title: Patient perspectives of dabigatran: analysis of online discussion forums.
abstract: BACKGROUND
  In 2010 the US FDA approved dabigatran, the first new anticoagulant for stroke prevention in non-valvular atrial fibrillation (AF) since 1954. To date there is little data that reflects the experiences and perceptions of real-world patients with dabigatran. The abundance of Internet-based discussion forums and support groups related to AF or anticoagulation may provide a low-cost resource for assessing patient experiences.
  
  
  OBJECTIVE
  The aim of this study was to determine patient experiences and perceptions regarding dabigatran through qualitative thematic content analysis of comments posted on publicly accessible virtual discussion forums and Internet support groups.
  
  
  METHODS
  Comments posted between January 2011 and September 2012 were downloaded from websites focusing on support of patients with AF or on anticoagulation therapy. Comments were analyzed for thematic content.
  
  
  RESULTS
  Five broad thematic categories emerged from the posted comments: general concerns about safety and efficacy, questions about indications and contraindications, questions about proper use and storage, questions about diet and drug restrictions, and experiences with perceived side effects. Our data revealed that a primary concern for patients taking dabigatran is the lack of antidote to reverse the effects of dabigatran if bleeding occurs. Several questions pertaining to the use of dabigatran with other medications or medical conditions were noted, and multiple patients expressed confusion about instructions for using dabigatran before and after medical procedures. An unexpected finding included several criticisms of the medication packaging, which many patients found inconvenient or difficult to open. Finally, several perceived side effects were noted, including some not reported in clinical trials.
  
  
  CONCLUSIONS
  Online communities may provide information about topics that are a concern to patients and that may not be discernible in clinical trials, such as medication side effects, proper use, and safety. Our data also highlighted potential topics that may not be a priority to researchers but are nevertheless important to patients (e.g. medication convenience or packaging). Despite the growing use of online health-related communities, very little research makes use of this low-cost resource for identifying patient interests regarding therapeutic treatments to guide patient-oriented research.
authors.affiliation: Comprehensive Access and Delivery Research and Evaluation (CADRE) Center, Iowa City VA Health Care System, Iowa City, IA, USA, mary-vaughan-sarrazin@uiowa.edu.
authors.forename: Mary S
authors.initials: MS
authors.lastname: Vaughan Sarrazin
authors.forename: Peter
authors.initials: P
authors.lastname: Cram
authors.forename: Alexandur
authors.initials: A
authors.lastname: Mazur
authors.forename: Melissa
authors.initials: M
authors.lastname: Ward
authors.forename: Heather Schacht
authors.initials: HS
authors.lastname: Reisinger
mesh_terms: D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D054626:Consumer Health Information / Q000379:methods*; D000069604:Dabigatran; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018565:Food-Drug Interactions; D006801:Humans; D061214:Patient Safety; D010465:Perception; D061108:Social Media; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D000069604:Dabigatran
references.citation: Psychiatr Rehabil J. 2002 Summer;26(1):70-7
references.pmid: 12171285
references.citation: J Med Internet Res. 2013 Jun 18;15(6):e124
references.pmid: 23778053
references.citation: Patient Educ Couns. 2013 Dec;93(3):426-32
references.pmid: 23669152
references.citation: Nature. 2009 Feb 19;457(7232):1012-4
references.pmid: 19020500
references.citation: Lancet. 2005 Feb 5-11;365(9458):475-81
references.pmid: 15705456
references.citation: Qual Health Res. 2005 Mar;15(3):325-45
references.pmid: 15761103
references.citation: BMJ. 2005 Dec 3;331(7528):1310-6
references.pmid: 16322018
references.citation: Stroke. 2013 Jun;44(6 Suppl 1):S38-40
references.pmid: 23709725
references.citation: N Engl J Med. 2010 Nov 4;363(19):1875-6
references.pmid: 21047252
references.citation: Circulation. 2006 Aug 15;114(7):e257-354
references.pmid: 16908781
references.citation: Curr Cardiol Rep. 2006 Sep;8(5):323-9
references.pmid: 16956446
references.citation: AMIA Annu Symp Proc. 2006;:244-8
references.pmid: 17238340
references.citation: BMC Psychiatry. 2003 Dec 10;3:19
references.pmid: 14664725
references.citation: Comput Inform Nurs. 2003 May-Jun;21(3):136-42
references.pmid: 12792194
references.citation: Circ Cardiovasc Qual Outcomes. 2011 May;4(3):313-20
references.pmid: 21540439
references.citation: Prim Care. 2013 Mar;40(1):109-34
references.pmid: 23402464
references.citation: Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21
references.pmid: 22949490
references.citation: Cochrane Database Syst Rev. 2011 Sep 07;(9):CD005025
references.pmid: 21901694
references.citation: Curr Probl Cardiol. 2005 Apr;30(4):175-233
references.pmid: 15778690
references.citation: Am J Health Syst Pharm. 2012 Sep 1;69(17):1473-84
references.pmid: 22899742
references.citation: J Am Med Inform Assoc. 2013 May 1;20(3):404-8
references.pmid: 23467469
references.citation: Clin Cardiol. 2012 Dec;35(12):730-7
references.pmid: 22811404
references.citation: J Med Internet Res. 2011 May 10;13(2):e36
references.pmid: 21558062
references.citation: J Thromb Thrombolysis. 2011 Apr;31(3):326-43
references.pmid: 21359645
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: JAMA. 2001 Jun 13;285(22):2864-70
references.pmid: 11401607